






Table of Contents

<i>Message from CEO</i>	2
<i>Tumor registry 2008 : Abstract</i>	4
<i>Annual Tumor Registry 2008</i>	5
<i>Distribution by Age & Sex, 10 Leading Site of Cancer, 10 Leading Site of Cancer 3 Years, Method of Diagnosis, Patient Category, Staging, Type of Primary Treatment, Patient Follow up and Nationality</i>	
<i>Review of Breast Cancer</i>	23
<i>Review of Lung Cancer</i>	31
<i>Review of Colorectal Cancer</i>	40
<i>Review of Hepatobiliary Cancer</i>	49
<i>Review of Prostate Cancer</i>	58
<i>Age Distribution in All Male Cancer Number of Case</i>	66
<i>Age Distribution in All Female Cancer Number of Case</i>	68
<i>Special articles : How Tumor Registry Predicts Outcome</i>	70
<i>Tumor Registry Team</i>	72

Wattanosoth Cancer Hospital

2008



Smoking is one of the causes of lung cancer. Lung cancer is still number one cancer in the world. Mortality rate of cancer is still not decreasing in the past 20 years.

Message from **CEO**

Public awareness for prevention, early diagnosis and detection in the earliest stage is the most efficient way to deal and cope with major diseases like "Cancer".

I am proud to welcome all of you to the Wattanosoth Tumor Registry 08. This worthwhile annual report delivers readers all statistical data which include demographic, diagnostic and therapeutic, distinguished according to gender and age, of all types of the reportable cancers diagnosed, or undertaken at Wattanosoth Hospital. This information has proven to be instrumental in monitoring and enhancing a better quality of patient care for people suffering from cancer. The publication also presents an overview of our experiences and a comparative patient analysis. I am confident that you will find this publication to be of great value.

All the accomplishments detailed in this annual report would not have been possible without the professional contribution and dedication of the Wattanosoth Tumor Registry Committee who sacrifice their time and deliver their expertise and effort.

In this connection, I wish to extend my sincere gratitude and appreciation to the Wattanosoth Tumor Registry Committee and to everyone who has contributed to this publication.

Chatree Duangnet, M.D. FAAP, FACMQ

Chief Executive Officer

*Bangkok Hospital Medical Center,
Bangkok Dusit Medical Services Pcl.
and Director of Wattanosoth Hospital*

Chatree Duangnet, M.D. FAAP, FACMQ

*Chief Executive Officer Bangkok Hospital Medical Center,
Bangkok Dusit Medical Services Pcl. and Director of Wattanosoth Hospital*

Tumor registry 2008 : *Abstract*

Total new cases diagnosed malignancy at Bangkok Hospital Medical Center is 1277 cases (excluding the hematologic and brain tumor). There was 8.4 percent decreasing in total number as compared to 1394 cases in year 2007. Sex ratio is 1:1 an age distribution is not changed as compared to year 2007. Patients who are between 50-69 YO are majority and accounted more than half of overall. Patient age group of 55-59 YO is accounted for almost 15 percents. Anyway, average age in female patients is slightly younger.

Top 5 malignancies are followings: 1) Breast (17.7 percent) 2) Lung (11.7 percent) 3) Colorectal (11.1 percent) 4) Hepatobiliary (9.2 percent) and 5) Prostate (6.4 percent). The top 5 trend is not different from in 3 years (2006-2008) collection (Breast, Colorectal, Lung, Liver and Prostate). Anyway, when compared to last year, overall numbers of cases in Colorectal and Prostate were dropped significantly 21 percent and 34 percent respectively. Contrast to Breast cancer and Liver cancer which are still rising in numbers 7.5 percent and 37 percent respectively. Lung cancer is the leading cancer in male for 3 years and still constant this year. Carcinoma of the cervix is still the second cancer of Female in BMC but number 9th in both sexes and dropped down 78 percent compared to year 2007. Skin and lymph node malignancies are stepping up and ranking at 6th and 7th this year.

Considering patients who received treatment at BMC, stage I is 24 percent, stage II 18.6 percent, stage III 17.5 percent and stage IV 24.4 percent. Unknown stage (due to lack of pertinent clinical information) is still high at 11.5 percent compared to 12 percent last year.


Considering the primary treatments that have been done in BMC, Surgery is still the majority (33 percent) followed by radiation (10 percent) and chemotherapy. Chemotherapy and targeted therapy show slightly decreasing trends from 9 to 5 percent. Intervention treatment is up from 2 to 4 percent.

Patients who were diagnosed cancer at BMC tend to decide receiving treatments at BMC, 34.5 percent (11.33 percent last year) and these patients decided to having primary treatment in other hospitals 12.6 percent (22 percent last year). Surprisingly, even patients who come from other hospitals for seeking second opinion at BMC only is significantly increased (more than one-fourth of all) but those who come and continue treatments at BMC is much lower than last year (61 percent dropped to 38 percent)

Patients who are still alive after diagnosing or treating cancer in year 2008 is 89 percent, one-third are alive without disease. Patient was dead with cancer as leading cause is 5 percent and with other disease is 1 percent. Rate of lost to follow up is decreased from 6 to 3 percent.

Ratio of Thai: non-Thai patient is 3:2 compared to 2:1 in year 2007. This changing ratio is also due to higher proportion of Foreigner patients which is rising for 9.4 percent this year. The top 5 rankings are UAE, Myanmar, Oman, Bangladesh, US and Ethiopia. The most inclining are from Oman, Qatar, Ethiopia and Myanmar.

DISTRIBUTION OF ALL CANCER BY AGE & SEX




DISTRIBUTION OF ALL CANCER BY AGE & SEX


Age Group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	0	0.00	1	0.16	1	0.08
10 - 14	2	0.32	1	0.16	3	0.23
15 - 19	4	0.63	5	0.78	9	0.70
20 - 24	5	0.79	4	0.62	9	0.70
25 - 29	6	0.95	8	1.24	14	1.10
30 - 34	7	1.11	28	4.35	35	2.74
35 - 39	23	3.63	36	5.59	59	4.62
40 - 44	36	5.69	71	11.02	107	8.38
45 - 49	47	7.42	81	12.58	128	10.02
50 - 54	55	8.69	75	11.65	130	10.18
55 - 59	91	14.38	91	14.13	182	14.25
60 - 64	92	14.53	58	9.01	150	11.75
65 - 69	107	16.90	67	10.40	174	13.63
70 - 74	60	9.48	48	7.45	108	8.46
75 - 79	49	7.74	33	5.12	82	6.42
80 - 84	32	5.06	27	4.19	59	4.62
85 - 89	12	1.90	4	0.62	16	1.25
90 - 94	5	0.79	4	0.62	9	0.70
95+	0	0.00	2	0.31	2	0.16
Total	633	100.00	644	100.00	1,277	100.00



THE 10 LEADING SITE OF CANCER 2008



TOP-10 OF CANCER IN MALE 2008




THE 10 LEADING SITE OF CANCER 2008

Code	Primary site	Male	Female	Total	Percent
C50	Breast	1	225	226	17.70
C33-C34	Lung	91	58	149	11.67
C18-C20	Colorectal	90	52	142	11.12
C22-C24	Liver	80	38	118	9.24
C61	Prostate gland	82	0	82	6.42
C43-C44	Skin	38	17	55	4.31
C81-C85	Lymph node	32	18	50	3.92
C16	Stomach	17	26	43	3.37
C53	Cervix	0	42	42	3.29
C73	Thyroid gland	14	27	41	3.21


THE 10 LEADING SITE OF CANCER IN MALE 2008

Code	Primary site	Number	Percent
C34	Lung	91	14.38
C18-C20	Colorectal	90	14.22
C61	Prostate gland	82	12.95
C22	Liver	80	12.64
C44	Skin	38	6.00
C81-C85	Lymph node	32	5.06
C67	Urinary bladder	29	4.58
C64	Kidney	20	3.16
C15	Esophagus	18	2.84
C16	Stomach	17	2.69

TOP-10 OF CANCER IN FEMALE 2008



TOP-10 OF CANCER ALL GENDER IN 2006, 2007, 2008




THE 10 LEADING SITE OF CANCER IN FEMALE 2008

Code	Primary site	Number	Percent
C50	Breast	225	34.94
C34	Lung	58	9.01
C18-C20	Colorectal	52	8.07
C53	Cervix	42	6.52
C22	Liver	38	5.90
C73	Thyroid gland	27	4.19
C16	Stomach	26	4.04
C56	Ovary	19	2.95
C54	Endometrium	18	2.80
C81-C85	Lymph node	18	2.80


THE 10 LEADING SITE OF CANCER ALL GENDER IN 2006, 2007, 2008

Code	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
C50	Breast	2	0.11	724	36.71	726	19.09
C18-C20	Colorectal	255	13.92	175	8.87	430	11.30
C33-C34	Lung	271	14.79	132	6.69	403	10.59
C22-C24	Liver & Hepatobiliary	192	10.48	88	4.46	280	7.36
C61	Prostate gland	279	15.23	0	0.00	279	7.33
C53	Cervix	0	0.00	178	9.03	178	4.68
C16	Stomach	57	3.11	60	3.04	117	3.08
C73	Thyroid gland	35	1.91	81	4.11	116	3.05
C11-C14	Head & Neck	75	4.09	37	1.88	112	2.94
C44	Skin	69	3.77	39	1.98	108	2.84

TOP-10 OF CANCER IN MALE IN 2006, 2007, 2008



TOP-10 OF CANCER IN FEMALE IN 2006, 2007, 2008




THE 10 LEADING SITE OF CANCER IN MALE IN 2006, 2007, 2008

Code	Primary site	Number	Percent
C61	Prostate gland	279	15.23
C33-C34	Lung	271	14.79
C18-C20	Colorectal	255	13.92
C22-C24	Liver & Hepatobiliary	192	10.48
C67	Urinary bladder	90	4.91
C11-C14	Head & Neck	75	4.09
C44	Skin	69	3.77
C16	Stomach	57	3.11
C15	Esophagus	54	2.95
C71	Brain	47	2.57


THE 10 LEADING SITE OF CANCER IN FEMALE IN 2006, 2007, 2008

Code	Primary site	Number	Percent
C50	Breast	724	36.71
C53	Cervix	178	9.03
C18-C20	Colorectal	175	8.87
C33-C34	Lung	132	6.69
C22-C24	Liver & Hepatobiliary	88	4.46
C73	Thyroid gland	81	4.11
C54	Endometrium	65	3.30
C56	Ovary	65	3.30
C16	Stomach	60	3.04
C44	Skin	39	1.98

METHOD OF DIAGNOSIS



PATIENT CATEGORY OF ALL CANCER



METHOD OF DIAGNOSIS

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	9	1.42	4	0.62	13	1.02
Other	93	14.69	106	16.46	199	15.58
Cytology	17	2.69	26	4.04	43	3.37
Histology	474	74.88	490	76.09	964	75.49
Imaging	40	6.32	18	2.80	58	4.54
Total	633	100.00	644	100.00	1,277	100.00


** Other = Previously diagnosed as Cancer from other hospital but no document of pathology

PATIENT CATEGORY OF ALL CANCER


Patient category	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Dx(Here)Rx(Other)	78	12.32	83	12.89	161	12.61
Dx(Here)Rx(Here)	230	36.33	211	32.76	441	34.53
Dx(Other)Rx(Here)	71	11.22	67	10.40	138	10.81
Dx(Other)Rx(Other)	171	27.01	179	27.80	350	27.41
Dx(Other)Rx(Other)Before	83	13.11	104	16.15	187	14.64
Total	633	100.00	644	100.00	1,277	100.00

** Dx = Diagnosis for Cancer (Dx by Pathology, Cytology or Imaging)
 Rx = Treatment
 Here = Within Bangkok Hospital Medical Center
 Other = Outside Bangkok Hospital Medical Center

STAGING



STAGING




STAGING

Stage	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	92	14.53	135	20.96	227	17.78
Stage II	76	12.01	127	19.72	203	15.90
Stage III	101	15.96	78	12.11	179	14.02
Stage IV	179	28.28	126	19.57	305	23.88
Non stage	26	4.11	23	3.57	49	3.84
Unspecified stage	159	25.12	155	24.07	314	24.59
Total	633	100.00	644	100.00	1,277	100.00


** Non stage = Carcinoma in situ and in tumor that has no TNM staging

Unspecified stage = Incomplete staging due to patient information is not enough


Female



STAGING (TREATMENT IN BMC ONLY)



STAGING (TREATMENT IN BMC ONLY)




STAGING (TREATMENT IN BMC ONLY)

Stage	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	77	20.05	107	28.01	184	24.02
Stage II	60	15.63	83	21.73	143	18.67
Stage III	79	20.57	55	14.40	134	17.49
Stage IV	111	28.91	76	19.90	187	24.41
Non stage	14	3.65	16	4.19	30	3.92
Unspecified stage	43	11.20	45	11.78	88	11.49
Total	384	100.00	382	100.00	766	100.00


** Non stage = Carcinoma in situ and in tumor that has no TNM staging

Unspecified stage = Incomplete staging due to Patient information is not enough


Female



TYPE OF PRIMARY TREATMENT




TYPE OF PRIMARY TREATMENT




TYPE OF PRIMARY TREATMENT

Type of Primary Treatment	Male	Female	Total
Surgery	197	224	421
External Radiotherapy	73	45	118
Brachytherapy	2	4	6
Targeted therapy	7	3	10
Nuclear Med. treatment	2	4	6
Palliative care	26	22	48
Chemotherapy	22	39	61
Immunotherapy	1	0	1
Hormone therapy	3	7	10
Intervention	37	15	52
Concurrent chemoradiation	15	18	33
Investigate	180	177	357
2nd Opinion	68	86	154
Total	633	644	1,277

Female



PATIENT FOLLOW UP



PATIENT FOLLOW UP

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
AWD	262	41.39	242	37.58	504	39.47
AOD	74	11.69	111	17.24	185	14.49
DWD	33	5.21	31	4.81	64	5.01
DOD	7	1.11	2	0.31	9	0.70
Loss F/U	26	4.11	11	1.71	37	2.90
No F/U	231	36.49	247	38.35	478	37.43
Total	633	100.00	644	100.00	1,277	100.00

** AWD = Alive with Disease

AOD = Alive without Disease


DWD = Dead with Disease

DOD = Dead without Disease

Loss F/U = Not attended

No F/U = Intend not to continue diagnosis or treatment at BMC


REFERING HOSPITAL




REFERING HOSPITAL

Referring Hospital	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
OTHER HOSPITAL	276	43.60	309	47.98	585	45.81
BGH only	151	23.85	81	12.58	232	18.17
BGH (ทรงส่งต่อภายในศูนย์การแพทย์รพ.กรุงเทพ)	109	17.22	96	14.91	205	16.05
WSH only	48	7.58	114	17.70	162	12.69
BPH (กรุงเทพ พญา)	16	2.53	6	0.93	22	1.72
SVH (สภิตเวชสุขุมวิท)	11	1.74	11	1.71	22	1.72
BNH (บางกอกเนอสซิ่งโฮม)	8	1.26	7	1.09	15	1.17
SSH (สภิตเวชศรีราชา)	0	0.00	11	1.71	11	0.86
BPK (กรุงเทพ ภูเก็ต)	7	1.11	2	0.31	9	0.70
BKH (กรุงเทพ ราชสีมา)	3	0.47	2	0.31	5	0.39
SNH (สภิตเวชศรีนครินทร์)	2	0.32	2	0.31	4	0.31
BHH (กรุงเทพ ภาดใหญ่)	1	0.16	1	0.16	2	0.16
BCH (กรุงเทพ จันทบุรี)	0	0.00	1	0.16	1	0.08
BSH (กรุงเทพ สมุย)	0	0.00	1	0.16	1	0.08
RAH (Royal Angkor)	1	0.16	0	0.00	1	0.08
BRH (กรุงเทพ ระยอง)	0	0.00	0	0.00	0	0.00
BTH (กรุงเทพ ตราด)	0	0.00	0	0.00	0	0.00
TOTAL	633	100.00	644	100.00	1,277	100.00

NATIONALITY



FOREIGN NATIONALITY



PATIENT NATIONALITY

Patient Nationality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
THAI	329	51.97	448	69.57	777	60.85
ARAB EMIRATES	36	5.69	37	5.75	73	5.72
MYANMAR	39	6.16	33	5.12	72	5.64
OMAN	28	4.42	17	2.64	45	3.52
BANGLADESH	24	3.79	14	2.17	38	2.98
AMERICA	29	4.58	3	0.47	32	2.51
ETHIOPIA	13	2.05	16	2.48	29	2.27
BRITISH	22	3.48	4	0.62	26	2.04
QATAR	12	1.90	12	1.86	24	1.88
JAPAN	15	2.37	5	0.78	20	1.57
OTHER	86	13.59	55	8.54	141	11.04
TOTAL	633	100.00	644	100.00	1,277	100.00


BREAST CANCER

PATHOLOGY ACCORDING OF BREAST CANCER


Tumor site	Number	
C50.0	Nipple	1
C50.1	Central portion of breast	0
C50.2	Upper-inner quadrant of breast	22
C50.3	Lower-inner quadrant of breast	12
C50.4	Upper-outer quadrant of breast	55
C50.5	Lower-outer quadrant of breast	10
C50.6	Axillary tail of breast	0
C50.8	Overlapping lesion of breast	0
C50.9	Breast, NOS	126

Pathology Report	Number	
M8000/3	Malignant neoplasm	49
M8140/3	Adenocarcinoma	2
M8200/3	Adenoid cystic carcinoma	2
M8201/3	Cribriform carcinoma	1
M8211/3	Tubular carcinoma	2
M8480/3	Mucinous carcinoma	3
M8500/3	Invasive ductal carcinoma	151
M8501/3	Comedocarcinoma	1
M8510/3	Medullary carcinoma	1
M8520/3	Lobular carcinoma	7
M8522/3	Lobular and ductal carcinoma	4
M8523/3	Invasive ductal and mucinous carcinoma	3

AGE & SEX




PATIENT CATEGORY



** Dx = Diagnosis for Breast cancer (Dx by Pathology, Cytology or Imaging)
 Rx = Treatment
 Here = Within Bangkok Hospital Medical Center
 Other = Outside Bangkok Hospital Medical Center

METHOD OF DIAGNOSIS




METHOD OF DIAGNOSIS

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	0	0.00	0	0.00	0	0.00
Other	0	0.00	45	20.00	45	19.91
Cytology	0	0.00	6	2.67	6	2.65
Histology	1	100.00	174	77.33	175	77.43
Imaging	0	0.00	0	0.00	0	0.00
Total	1	100.00	225	100.00	226	100.00


** Other = Previously diagnosed as Breast cancer from other hospital but no document of pathology



METHOD OF DIAGNOSIS (TREATMENT IN BMC ONLY)



STAGING



METHOD OF DIAGNOSIS (TREATMENT IN BMC ONLY)

Method of diagnosis	Female	
	Number	Percent
Biochemical	0	0.00
Other	8	6.15
Cytology	2	1.54
Histology	120	92.31
Imaging	0	0.00
Total	130	100.00


** Other = Previously diagnosed as Breast cancer from other hospital but no document of pathology

STAGING

Stage	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	0	0.00	66	29.33	66	29.20
Stage II	0	0.00	70	31.11	70	30.97
Stage III	0	0.00	29	12.89	29	12.83
Stage IV	0	0.00	14	6.22	14	6.19
Unspecified stage	1	100.00	46	20.44	47	20.80
Total	1	100.00	225	100.00	226	100.00

** Unspecified stage = Cannot staging in Breast cancer due to patient information is not enough

STAGING (TREATMENT IN BMC ONLY)



STAGING (TREATMENT IN BMC ONLY)

Stage	Number	Percent
Stage I	48	36.92
Stage II	43	33.08
Stage III	22	16.92
Stage IV	9	6.92
Unspecified stage	8	6.15
Total	130	100.00

** Unspecified stage = Cannot staging in Breast cancer due to patient information is not enough

TYPE OF TREATMENT (TREATMENT IN BMC ONLY)

Treatment	Total	
	Number	Percent
SUR. only	28	12.39
RT only	1	0.44
CT only	6	2.65
SUR.+CT	36	15.93
SUR.+Targeted therapy	2	0.88
SUR.+Hormone	28	12.39
RT+CT	1	0.44
CT+Hormone	1	0.44
SUR.+RT+CT	23	10.18
SUR.+RT+Hormone	16	7.08
SUR.+CT+Hormone	11	4.87
RT+CT+Hormone	2	0.88
SUR.+RT+CT+Hormone	22	9.73
Investigate	41	18.14
2 nd Opinion	8	3.54
Total	226	100.00

** SUR. = Surgery
 RT = External radiation therapy
 CT = Chemotherapy
 Hormone = Hormonal therapy
 2nd Opinion = Consult only (No treatment)


OVERALL TYPE OF TREATMENT

Treatment	Total	
	Number	Percent
SUR. only	28	12.39
RT only	1	0.44
CT only	6	2.65
H only	1	0.44
SUR.+RT	10	4.42
SUR.+CT	36	15.93
SUR.+RT+CT	23	10.18
SUR.+RT+Hormone	17	7.52
SUR.+RT+CT+Hormone	22	9.73
SUR.+CT+Hormone	9	3.98
SUR.+Hormone	19	8.41
SUR.+Targeted therapy	2	0.88
RT+CT	1	0.44
RT+CT+Hormone	1	0.44
CT+Hormone	1	0.44
Investigate	41	18.14
2 nd Opinion	8	3.54
Total	226	100.00

** SUR. = Surgery
 RT = External radiation therapy
 CT = Chemotherapy
 Hormone = Hormonal therapy
 2nd Opinion = Consult only (No treatment)

FOLLOW UP STATUS

Follow up status	Total	
	Number	Percent
AWD	73	32.30
AOD	59	26.11
DWD	0	0.00
DOD	0	0.00
Loss F/U	1	0.44
No F/U	93	41.15
Total	226	100.00



** AWD = Alive with Disease

AOD = Alive without Disease


DWD = Dead with Disease

DOD = Dead without Disease

Loss F/U = Not attended

No F/U = Intend not to continue diagnosis or treatment at BMC

PATIENT NATIONALITY



LUNG CANCER


PATHOLOGY ACCORDING OF LUNG CANCER

Tumor site	Number	
C34.0	Main bronchus	4
C34.1	Upper lobe, lung	35
C34.2	Middle lobe, lung	2
C34.3	Lower lobe, lung	27
C34.8	Overlapping lesion of lung	0
C34.9	Lung, NOS	81


Pathology Report	Number	
M8000/3	Malignant neoplasm	38
M8010/3	Carcinoma, NOS	1
M8012/3	Large cell carcinoma, NOS	1
M8020/3	Carcinoma undifferentiated, NOS	1
M8021/3	Carcinoma anaplastic, NOS	1
M8033/3	Pseusarcomatous carcinoma	1
M8041/3	Small cell carcinoma, NOS	5
M8045/3	Combined small cell carcinoma	4
M8046/3	Non small cell carcinoma	26
M8070/3	Squamous cell carcinoma, NOS	15
M8140/3	Adenocarcinoma, NOS	31
M8250/3	Bronchiolo-aveolar adenocarcinoma, NOS	20
M8252/3	Bronchiolo-aveolar carcinoma, non mucinous	1
M8260/3	Papillary adenocarcinoma, NOS	3
M8481/3	Mucin-producing adenocarcinoma	1




AGE & SEX



METHOD OF DIAGNOSIS



PATIENT CATEGORY



** Dx = Diagnosis for Lung cancer (Dx by Pathology, Cytology or Imaging)
 Rx = Treatment
 Here = Within Bangkok Hospital Medical Center
 Other = Outside Bangkok Hospital Medical Center


METHOD OF DIAGNOSIS

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	0	0.00	0	0.00	0	0.00
Other	17	18.68	13	22.41	30	20.13
Cytology	10	10.99	3	5.17	13	8.72
Histology	56	61.54	38	65.52	94	63.09
Imaging	8	8.79	4	6.90	12	8.05
Total	91	100.00	58	100.00	149	100.00


** Other = Previously diagnosed as Lung cancer from other hospital but no document of pathology



METHOD OF DIAGNOSIS (TREATMENT IN BMC ONLY)



STAGING



METHOD OF DIAGNOSIS (TREATMENT IN BMC ONLY)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	0	0.00	0	0.00	0	0.00
Other	8	13.79	3	9.68	11	12.36
Cytology	6	10.34	3	9.68	9	10.11
Histology	39	67.24	22	70.97	61	68.54
Imaging	5	8.62	3	9.68	8	8.99
Total	58	100.00	31	100.00	89	100.00


** Other = Previously diagnosed as Lung cancer from other hospital but no document of pathology

STAGING

Stage	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	7	7.69	6	10.34	13	8.72
Stage II	2	2.20	2	3.45	4	2.68
Stage III	9	9.89	8	13.79	17	11.41
Stage IV	57	62.64	33	56.90	90	60.40
Unspecified stage	16	17.58	9	15.52	25	16.78
Total	91	100.00	58	100.00	149	100.00

** Unspecified stage = Cannot staging in Lung cancer due to patient information is not enough

STAGING (TREATMENT IN BMC ONLY)



STAGING (TREATMENT IN BMC ONLY)

Stage	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	7	12.07	6	19.35	13	14.61
Stage II	1	1.72	1	3.23	2	2.25
Stage III	6	10.34	4	12.90	10	11.24
Stage IV	40	68.97	19	61.29	59	66.29
Unspecified stage	4	6.90	1	3.23	5	5.62
Total	58	100.00	31	100.00	89	100.00

** Unspecified stage = Cannot staging in Lung cancer due to patient information is not enough

TYPE OF TREATMENT (TREATMENT IN BMC ONLY)

Treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR. only	7	7.69	8	13.79	15	10.07
RT only	19	20.88	5	8.62	24	16.11
CT only	6	6.59	3	5.17	9	6.04
SUR.+CT	1	1.10	2	3.45	3	2.01
RT+CT	5	5.49	3	5.17	8	5.37
SUR.+Targeted therapy	0	0.00	1	1.72	1	0.67
SUR.+RT+Targeted therapy	1	1.10	0	0.00	1	0.67
Bracytherapy	0	0.00	1	1.72	1	0.67
Targeted therapy	4	4.40	1	1.72	5	3.36
RT+Targeted therapy	4	4.40	2	3.45	6	4.03
RT+Targeted therapy+Hormone	0	0.00	1	1.72	1	0.67
RT+CT+Concurrent CT-RT	1	1.10	0	0.00	1	0.67
RT+CT+Targeted therapy	1	1.10	1	1.72	2	1.34
CT+Targeted therapy	2	2.20	0	0.00	2	1.34
Concurrent CT-RT	3	3.30	0	0.00	3	2.01
Concurrent CT-RT+Trageted therapy	0	0.00	1	1.72	1	0.67
Palliative care	5	5.50	3	5.17	8	5.37
Investigate	26	28.57	14	24.14	40	26.85
2 nd Opinion	6	6.59	12	20.69	18	12.08
Total	91	100.00	58	100.00	149	100.00

** SUR. = Surgery

RT = External radiation therapy

CT = Chemotherapy

2nd Opinion = Consult only (No treatment)

OVERALL TYPE OF TREATMENT


Treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR. only	8	8.79	10	17.24	18	12.08
RT only	11	12.09	3	5.17	14	9.40
CT only	9	9.89	7	12.07	16	10.74
SUR.+RT	0	0.00	1	1.72	1	0.67
SUR.+CT	1	1.10	2	3.45	3	2.01
SUR.+RT+CT	7	7.69	2	3.45	9	6.04
RT+CT	8	8.79	5	8.62	13	8.72
SUR.+Targeted therapy	0	0.00	1	1.72	1	0.67
SUR.+RT+Targeted therapy	1	1.10	0	0.00	1	0.67
SUR.+CT+Targeted therapy	1	1.10	0	0.00	1	0.67
SUR.+CT+Bracytherapy	0	0.00	1	1.72	1	0.67
RT+CT+Targeted therapy	2	2.20	1	1.72	3	2.01
RT+Targeted therapy+Hormone	0	0.00	1	1.72	1	0.67
CT+Targeted therapy	2	2.20	0	0.00	2	1.34
RT+Targeted therapy	3	3.30	2	3.45	5	3.36
Targeted therapy	3	3.30	1	1.72	4	2.68
Concurrent CT-RT	5	5.49	0	0.00	5	3.36
Concurrent CT-RT+Targeted therapy	0	0.00	1	1.72	1	0.67
Investigate	21	23.08	11	18.97	32	21.48
Palliative care	4	4.40	1	1.72	5	3.36
2 nd Opinion	5	5.49	8	13.79	13	8.72
Total	91	100.00	58	100.00	149	100.00

** SUR. = Surgery
 RT = External radiation therapy
 CT = Chemotherapy
 Hormone = Hormonal therapy
 2nd Opinion = Consult only (No treatment)


FOLLOW UP STATUS

Follow up status	Total	
	Number	Percent
AWD	64	42.95
AOD	7	4.70
DWD	15	10.07
DOD	2	1.34
Loss F/U	2	1.34
No F/U	59	39.60
Total	149	100.00

** AWD = Alive with Disease
 AOD = Alive without Disease
 DWD = Dead with Disease
 DOD = Dead without Disease
 Loss F/U = Not attended
 No F/U = Intend not to continue diagnosis or treatment at BMC



PATIENT NATIONALITY




COLORECTAL CANCER

PATHOLOGY ACCORDING OF COLORECTAL CANCER


Tumor site		Number
C18.0	Cecum colon	6
C18.1	Appendix	0
C18.2	Ascending colon	7
C18.3	Hepatic flexure of colon	4
C18.4	Transverse colon	9
C18.5	Splenic flexure of colon	6
C18.6	Descending colon	7
C18.7	Sigmoid colon	32
C18.9	Colon, NOS	25
C19.9	Rectosigmoid colon	7
C20.9	Rectum	39

Pathology Report		Number
M8000/3	Malignant neoplasm	35
M8140/3	Adenocarcinoma	95
M8210/3	Polypoid adenocarcinoma	1
M8240/3	Carcinoid tumor	2
M8246/3	Neuroendocrine carcinoma	1
M8480/3	Mucinous adenocarcinoma	2
M8481/3	Mucin producing adenocarcinoma	4
M8490/3	Signet ring cell adenocarcinoma	1
M8560/3	Adenosquamous carcinoma	1

AGE & SEX




PATIENT CATEGORY




** Dx = Diagnosis for Colorectal cancer (Dx by Pathology, Cytology or Imaging)
 Rx = Treatment
 Here = Within Bangkok Hospital Medical Center
 Other = Outside Bangkok Hospital Medical Center

METHOD OF DIAGNOSIS



METHOD OF DIAGNOSIS (TREATMENT IN BMC ONLY)



METHOD OF DIAGNOSIS

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	0	0.00	0	0.00	0	0.00
Other	23	25.56	10	19.23	33	23.24
Cytology	0	0.00	0	0.00	0	0.00
Histology	67	74.44	41	78.85	108	76.06
Imaging	0	0.00	1	1.92	1	0.70
Total	90	100.00	52	100.00	142	100.00


** Other = Previously diagnosed as Colorectal cancer from other hospital but no document of pathology

METHOD OF DIAGNOSIS (TREATMENT IN BMC ONLY)


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	0	0.00	0	0.00	0	0.00
Other	5	10.00	2	8.33	7	9.46
Cytology	0	0.00	0	0.00	0	0.00
Histology	45	90.00	22	91.67	67	90.54
Imaging	0	0.00	0	0.00	0	0.00
Total	50	100.00	24	100.00	74	100.00

** Other = Previously diagnosed as Colorectal cancer from other hospital but no document of pathology

STAGING



STAGING (TREATMENT IN BMC ONLY)



STAGING

Stage	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	6	6.67	3	5.77	9	6.34
Stage II	9	10.00	8	15.38	17	11.97
Stage III	25	27.78	9	17.31	34	23.94
Stage IV	22	24.44	13	25.00	35	24.65
Unspecified stage	28	31.11	19	36.54	47	33.10
Total	90	100.00	52	100.00	142	100.00

** Unspecified stage = Incomplete staging due to patient information is not enough

STAGING (TREATMENT IN BMC ONLY)

Stage	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	5	10.00	2	8.33	7	9.46
Stage II	5	10.00	5	20.83	10	13.51
Stage III	22	44.00	7	29.17	29	39.19
Stage IV	13	26.00	6	25.00	19	25.68
Unspecified stage	5	10.00	4	16.67	9	12.16
Total	50	100.00	24	100.00	74	100.00

** Unspecified stage = Incomplete staging due to patient information is not enough

TYPE OF TREATMENT (TREATMENT IN BMC ONLY)

Treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR. only	21	23.33	13	25.00	34	23.94
CT only	1	1.11	1	1.92	2	1.41
Hormone only	1	1.11	0	0.00	1	0.70
SUR.+RT	1	1.11	0	0.00	1	0.70
SUR.+CT	18	20.00	5	9.62	23	16.20
SUR.+RT+CT	1	1.11	0	0.00	1	0.70
SUR.+Concurrent CT-RT	1	1.11	0	0.00	1	0.70
SUR.+Concurrent CT-RT+CT	1	1.11	0	0.00	1	0.70
SUR.+CT+Targeted therapy	0	0.00	1	1.92	1	0.70
Palliative care	4	4.44	3	5.77	7	4.93
CT+Targeted therapy	1	1.11	0	0.00	1	0.70
Intervention	0	0.00	1	1.92	1	0.70
Investigate	32	35.56	23	44.23	55	38.73
2 nd Opinion	8	8.89	5	9.62	13	9.15
Total	90	100.00	52	100.00	142	100.00

** SUR. = Surgery

RT = External radiation therapy

CT = Chemotherapy

Hormone = Hormonal therapy

2nd Opinion = Consult only (No treatment)

OVERALL TYPE OF TREATMENT

Treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR. only	28	31.11	15	28.85	43	30.28
CT only	2	2.22	0	0.00	2	1.41
SUR.+RT	1	1.11	0	0.00	1	0.70
SUR.+CT	25	27.78	15	28.85	40	28.17
RT+CT	1	1.11	0	0.00	1	0.70
SUR.+RT+CT	9	10.00	0	0.00	9	6.34
SUR.+CT+Hormone	0	0.00	1	1.92	1	0.70
SUR.+CT+Intervention	1	1.11	0	0.00	1	0.70
SUR.+CT+Targetrapy	2	2.22	1	1.92	3	2.11
Intervestigate	19	21.11	16	30.77	35	24.65
Palliative care	0	0.00	2	3.85	2	1.41
2 nd Opinion	2	2.22	2	3.85	4	2.82
Total	90	100.00	52	100.00	142	100.00

** SUR. = Surgery

RT = External radiation therapy

CT = Chemotherapy

Hormone = Hormonal therapy


2nd Opinion = Consult only (No treatment)

FOLLOW UP STATUS


Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
AWD	34	37.78	20	38.46	54	38.03
AOD	7	7.78	3	5.77	10	7.04
DWD	5	5.56	1	1.92	6	4.23
DOD	0	0.00	0	0.00	0	0.00
Loss F/U	3	3.33	1	1.92	4	2.82
No F/U	41	45.56	27	51.92	68	47.89
Total	90	100.00	52	100.00	142	100.00

** AWD = Alive with Disease
 AOD = Alive without Disease
 DWD = Dead with Disease
 DOD = Dead without Disease
 Loss F/U = Not attended
 No F/U = Intend not to continue diagnosis or treatment at BMC

FOLLOW UP STATUS



PATIENT NATIONALITY



HEPATOBIILIARY CANCER


PATHOLOGY ACCORDING OF HEPATOBIILIARY CANCER

Tumor site		Number
C22.0	Liver	89
C22.1	Liver (Pathology is M8160/3)	12
C23.9	Gall bladder	8
C24.0	Extrahepatic bile duct	2
C24.1	Ampullar of vater	7


Pathology Report		Number
M8000/3	Malignant neoplasm	65
M8140/3	Adenocarcinoma, NOS	14
M8160/3	Cholangiocarcinoma	13
M8170/3	Hepatocellular carcinoma, NOS	23
M8180/3	Combined hepatocellular carcinoma and cholangiocarcinoma	1
M8240/3	Carcinoid tumor	1
M9120/3	Hemangiosarcoma	1




AGE & SEXES



METHOD OF DIAGNOSIS



PATIENT CATEGORY




** Dx = Diagnosis for Hepatobiliary cancer (Dx by Pathology, Cytology or Imaging)
 Rx = Treatment
 Here = Within Bangkok Hospital Medical Center
 Other = Outside Bangkok Hospital Medical Center

METHOD OF DIAGNOSIS


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	9	11.25	4	10.53	13	11.02
Other	10	12.50	3	7.89	13	11.02
Cytology	0	0.00	0	0.00	0	0.00
Histology	33	41.25	20	52.63	53	44.92
Imaging	28	35.00	11	28.95	39	33.05
Total	80	100.00	38	100.00	118	100.00

** Other = Previously diagnosed as Hepatobiliary cancer from other hospital but no document of pathology

METHOD OF DIAGNOSIS (TREATMENT IN BMC ONLY)



STAGING



METHOD OF DIAGNOSIS (TREATMENT IN BMC ONLY)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	0	12.73	3	12.00	10	12.50
Other	0	10.91	3	12.00	9	11.25
Cytology	0	0.00	0	0.00	0	0.00
Histology	0	40.00	11	44.00	33	41.25
Imaging	0	36.36	8	32.00	28	35.00
Total	0	100.00	25	100.00	80	100.00


** Other = Previously diagnosed as Hepatobiliary cancer from other hospital but no document of pathology

STAGING

Stage	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	12	15.00	4	10.53	16	13.56
Stage II	17	21.25	9	23.68	26	22.03
Stage III	16	20.00	5	13.16	21	17.80
Stage IV	15	18.75	9	23.68	24	20.34
Unspecified stage	20	25.00	11	28.95	31	26.27
Total	80	100.00	38	100.00	118	100.00

** Unspecified stage = Incomplete staging due to patient information is not enough

STAGING (TREATMENT IN BMC ONLY)



STAGING (TREATMENT IN BMC ONLY)

Stage	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	8	14.55	3	12.00	11	13.75
Stage II	16	29.09	8	32.00	24	30.00
Stage III	13	23.64	3	12.00	16	20.00
Stage IV	10	18.18	6	24.00	16	20.00
Unspecified stage	8	14.55	5	20.00	13	16.25
Total	55	100.00	25	100.00	80	100.00

** Unspecified stage = Incomplete staging due to patient information is not enough

TYPE OF TREATMENT (TREATMENT IN BMC ONLY)

Treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR. Only	8	10.00	2	5.26	10	8.47
RT only	3	3.75	1	2.63	4	3.39
CT only	2	2.50	1	2.63	3	2.54
Intervention only	31	38.75	13	34.21	44	37.29
SUR.+RT	1	1.25	1	2.63	2	1.69
SUR.+Intervention	0	0.00	1	2.63	1	0.85
RT+Targeted therapy	1	1.25	0	0.00	1	0.85
Targeted therapy	2	2.50	0	0.00	2	1.69
Intervention+RT	1	1.25	0	0.00	1	0.85
Intervention+Targeted therapy	3	3.75	1	2.63	4	3.39
Concurrent CT-RT	0	0.00	1	2.63	1	0.85
Intervention+RT+Targeted therapy	1	1.25	0	0.00	1	0.85
Investigate	12	15.00	6	15.79	18	15.25
Palliative care	2	2.50	4	10.53	6	5.08
2 nd Opinion	13	16.25	7	18.42	20	16.95
Total	80	100.00	38	100.00	118	100.00

** SUR. = Surgery

RT = External radiation therapy

CT = Chemotherapy

2nd Opinion = Consult only (No treatment)

OVERALL TYPE OF TREATMENT

Treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR. Only	10	12.50	5	13.16	15	12.71
RT only	1	1.25	1	2.63	2	1.69
CT only	1	1.25	1	2.63	2	1.69
Intervention only	31	38.75	13	34.21	44	37.29
Targeted therapy	2	2.50	0	0.00	2	1.69
SUR.+RT	2	2.50	1	2.63	3	2.54
SUR.+CT	1	1.25	0	0.00	1	0.85
SUR.+Intervention	4	5.00	1	2.63	5	4.24
SUR.+RT+CT	1	1.25	0	0.00	1	0.85
RT+Intervention	2	2.50	0	0.00	2	1.69
RT+Targeted therapy	1	1.25	0	0.00	1	0.85
Intervention+Targeted therapy	2	2.50	1	2.63	3	2.54
Intervention+Concurrent CT-RT	0	0.00	1	2.63	1	0.85
RT+Intervention+Targeted therapy	1	1.25	0	0.00	1	0.85
SUR.+Intervention+Targeted therapy	1	1.25	0	0.00	1	0.85
Investigate	11	13.75	5	13.16	16	13.56
Palliative care	2	2.50	4	10.53	6	5.08
2 nd Opinion	7	8.75	5	13.16	12	10.17
Total	80	100.00	38	100.00	118	100.00


** SUR. = Surgery
 RT = External radiation therapy
 CT = Chemotherapy
 2nd Opinion = Consult only (No treatment)

FOLLOW UP STATUS


Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
AWD	36	45.00	18	47.37	54	45.76
AOD	0	0.00	0	0.00	0	0.00
DWD	7	8.75	9	23.68	16	13.56
DOD	0	0.00	0	0.00	0	0.00
Loss F/U	13	16.25	2	5.26	15	12.71
No F/U	24	30.00	9	23.68	33	27.97
Total	80	100.00	38	100.00	118	100.00

** AWD = Alive with Disease
 AOD = Alive without Disease
 DWD = Dead with Disease
 DOD = Dead without Disease
 Loss F/U = Not attended
 No F/U = Intend not to continue diagnosis or treatment at BMC

FOLLOW UP STATUS



PATIENT NATIONALITY




PROSTATE CANCER


PATHOLOGY ACCORDING OF PROSTATE GLAND CANCER

Tumor site		Male	Female	Total
Pathology Report		Number		
C61.9	Prostate gland			82
M8000/3	Malignant neoplasm			21
M8041/3	Small cell carcinoma, NOS			1
M8120/3	Transitional cell carcinoma, NOS			1
M8140/3	Adenocarcinoma, NOS			57
M8550/3	Acinar cell carcinoma			1
M8935/3	Stromal sarcoma, NOS			1

AGE & SEX




PATIENT CATEGORY




** Dx = Diagnosis for Prostate gland cancer (Dx by Pathology, Cytology or Imaging)
 Rx = Treatment
 Here = Within Bangkok Hospital Medical Center
 Other = Outside Bangkok Hospital Medical Center

METHOD OF DIAGNOSIS



METHOD OF DIAGNOSIS (TREATMENT IN BMC ONLY)



METHOD OF DIAGNOSIS

Method of diagnosis	Number	Percent
Biochemical	0	0.00
Other	20	24.39
Cytology	0	0.00
Histology	62	75.61
Imaging	0	0.00
Total	82	100.00


** Other = Previously diagnosed as Prostate gland cancer from other hospital but no document of pathology

METHOD OF DIAGNOSIS (TREATMENT IN BMC ONLY)


Method of diagnosis	Number	Percent
Biochemical	0	0.00
Other	5	11.11
Cytology	0	0.00
Histology	40	88.89
Imaging	0	0.00
Total	45	100.00

** Other = Previously diagnosed as Prostate gland cancer from other hospital but no document of pathology

STAGING



STAGING (TREATMENT IN BMC ONLY)



STAGING

Stage	Number	Percent
Stage I	11	13.41
Stage II	19	23.17
Stage III	18	21.95
Stage IV	19	23.17
Unspecified stage	15	18.29
Total	82	100.00

** Unspecified stage = Incomplete staging due to patient information is not enough

STAGING (TREATMENT IN BMC ONLY)

Stage	Number	Percent
Stage I	7	15.56
Stage II	13	28.89
Stage III	13	28.89
Stage IV	10	22.22
Unspecified stage	2	4.44
Total	45	100.00

** Unspecified stage = Incomplete staging due to patient information is not enough

TYPE OF TREATMENT (TREATMENT IN BMC ONLY)

Treatment	Male	
	Number	Percent
SUR. only	17	20.73
RT only	9	10.98
Brachytherapy	2	2.44
Hormone only	2	2.44
SUR.+RT	5	6.10
SUR.+Brachytherapy	2	2.44
SUR.+Hormone	4	4.88
RT+Hormone	2	2.44
SUR.+Hormone	1	1.22
Investigate	28	34.15
Palliative care	1	1.22
2 nd Opinion	9	10.98
Total	82	100.00

** SUR. = Surgery
 RT = External radiation therapy
 Hormone = Hormonal therapy
 2nd Opinion = Consult only (No treatment)

OVERALL TYPE OF TREATMENT


Treatment	Male	
	Number	Percent
SUR. only	19	23.17
RT only	6	7.32
Brachytherapy	2	2.44
RT+CT	1	1.22
SUR.+RT+Hormone	5	6.10
RT+Hormone	2	2.44
SUR.+Brachytherapy	2	2.44
RT+Brachytherapy	1	1.22
Hormone only	2	2.44
SUR.+RT	5	6.10
SUR.+Hormone	6	7.32
Investigate	24	29.27
2 nd Opinion	7	8.54
Total	82	100.00

** SUR. = Surgery
 RT = External radiation therapy
 Hormone = Hormonal therapy
 2nd Opinion = Consult only (No treatment)


FOLLOW UP STATUS

Follow up status	Number	Percent
AWD	34	41.46
AOD	12	14.63
DWD	1	1.22
DOD	0	0.00
Loss F/U	2	2.44
No F/U	33	40.24
Total	82	100.00

** AWD = Alive with Disease
 AOD = Alive without Disease
 DWD = Dead with Disease
 DOD = Dead without Disease
 Loss F/U = Not attended
 No F/U = Intend not to continue diagnosis or treatment at BMC



PATIENT NATIONALITY



How tumor registry predicts outcome?

Associate Professor Komgrit Tanisaro, MD


When ones think about tumor registry, they figure about numerous numbers, graphs and statistics. Someone may say it s just telling what has been going on cancer patient report and most of them will question how those huge data impact to our clinical practice.

Stepping up from those challenges, Tumor registry in some hospitals has been showing benefits in clinical or business management. Wattanosoth hospital has used annual report to plan for next coming year strategic planning; for example, we have known in year 2006, 2007 that we had been dealing with stage IV disease in at least one-fourth of patients therefore we have built palliative care unit and developed more treatment intervention serving those patients. Another example is about utilization of chemotherapeutic unit which we found only 10 percent of overall patients received the standard regimens. This lead us to create some exploration and root cause analysis.

We are running the hospital-based tumor registry for 3 years after grand opening in year 2006, three annual tumor registry were reported (include this issue). Three year in collecting the data may be not enough to tell how good the hospital team and medical staffs treat patients and cancer, particularly on the most valid clinical outcome "patient survivals" which is not just telling how many cases were treated, live and died or how often we did the complication in our procedure?

We have tried to analyze on the liver cancer patients (Hepatocellular carcinoma) which is second most common cancer in the country and number 4 in our hospital. The reason behind this selection is that the past 10 years international survival was very low (5 years survival is less than 10 percent) compared to other cancers and this will be reliable analysis if our follow-up is just 3 years.

OVERALL STAGE



We found that the liver cancer treatment regimens in our hospital are not varied from the international benchmarking, for example; surgical cases were around 12 percent and interventional radiology cases were 50 percent. The one year survival is rather satisfactory (88 percent) when compared to International data. We have calculated the 2-5 years survival and also median survival but those resulted in unreliable summary causes the registry was very short.

The above paragraph has confirmed us that our registry is now running in the right tract. With these format and continued improvement, in next few years we may know the correct answer of how good we treat and care of our patients in almost all cancers and all stages.


References;

- 1. Survey of HCC treatments in Korea. Courtesy to Joong-Won Park, MD, National Cancer Center*
- 2. Sean F. Itzkuse,* Katherine A. McGlynn, and Marsha E. Reichman . Journal of Clinical Oncology 2008.20.7753 Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005.*



Tumor Registry *Team*

- | | |
|---------------------------------|---------------------|
| 1. Surachai Sitawarin, M.D | Chairperson |
| 2. Komgrit Tanisaro, M.D | Vice Chairperson |
| 3. Saengduan Chindavijak, M.D | Committee Member |
| 4. Natthaphom Kanchanaporn, M.D | Committee Member |
| 5. Picheat Pariyarungsi | Committee Member |
| 6. Panissara Onlamoon | Secretary |
| 7. Waraphorn Chomphu | Secretary Assistant |



All Image illustrations (oil on canvas) are courtesy from Sandy Chindavijak, MD.

